FOREIGN PRODUCERS'/EXPORTERS' QUESTIONNAIRE

CERTAIN PEA PROTEIN FROM CHINA

This questionnaire must be received by the Commission by <u>July 26, 2023</u>
See last page for instructions regarding how to file this questionnaire.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its antidumping and countervailing duty investigations concerning high protein content pea protein ("HPC pea protein") from China (Inv. Nos. 701-TA-692 and 731-TA-1628 (Preliminary)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your firm's possession (19 U.S.C. § 1333(a)).

Name of firm

Website									
Has your firm January 1, 20	•	ported HPC pea prote	ein (as defined	on next pa	ge) from Ch	ina at any t	time since	:	
□ NO	(Sign the certif	cation below and promp	ptly return only	this page of	the question	naire to the	Commissio	n)	
YES	(Complete all p	arts of the questionnair	e, and return the	e entire que	stionnaire to	the Commis	sion)		
•		he Commission <i>Dro</i> oinv/. (PIN: PEA). S	•	•		•			
ledge and belief a	nd understand	supplied in response that the information	submitted is	subject to	audit and v	erification	by the Co	ommissio	ı. By
ledge and belief a s of this certificat mation provided in ommission on the s undersigned, ack	nd understand tion I also gra this questionn same or similar nowledge that	supplied in response that the information at consent for the C aire and throughout merchandise. information submitt	e to this ques submitted is s Commission, a this proceedin	subject to o and its em ng in any o se to this r	audit and voloyees an ther impor	erification d contract t-injury pro informatio	by the Co personne oceedings on and th	ommission el, to use conducte roughout	the d by
ledge and belief a s of this certificat nation provided in ommission on the s undersigned, ack eding or other pro nnel (a) for develo ws, and evaluatio ndix 3; or (ii) by U.	nd understand tion I also gra this questionn same or similar nowledge that oceedings may oping or mainto ns relating to S. government	supplied in response that the information nt consent for the C aire and throughout merchandise.	e to this quest submitted is sommission, a this proceeding ted in responsused: (i) by the this or a relationnel, and operact personnel,	subject to o and its em ag in any o se to this r se Commiss ted proceed perations o	audit and voloyees an ther imporequest for ion, its emding, or (b) f the Com	erification d contract t-injury pro informatio ployees an in internal mission inc	by the Co personne oceedings on and the d Offices, I investigo cluding u	ommission el, to use conducte roughout and con ations, au nder 5 L	the d by this tract dits,
ledge and belief a s of this certificat nation provided in ommission on the s undersigned, ack eding or other pro nnel (a) for develo ws, and evaluatio ndix 3; or (ii) by U.	nd understand tion I also gra this questionn same or similar nowledge that occedings may oping or maintons relating to S. government sign appropriate	supplied in response that the information of consent for the Caire and throughout merchandise. Information submittive disclosed to and the ining the records of the programs, person the programs of the programs, person the programs of the prog	e to this quest submitted is submitted is submitsion, a this proceeding ted in responsused: (i) by the this or a relationnel, and operact personnel, ements.	subject to o and its em ag in any o se to this r se Commiss ted proceed perations o	audit and voloyees an ther imporequest for ion, its emding, or (b) f the Com	erification d contract t-injury pro informatio ployees an in internal mission inc	by the Co personne oceedings on and the d Offices, I investigo cluding u	ommission el, to use conducte roughout and con ations, au nder 5 L	the d by this tract dits,

PART I.—GENERAL INFORMATION

Background.--This proceeding was instituted in response to petitions filed on July 12, 2023, by PURIS Proteins LLC, Minneapolis, Minnesota. Countervailing and/or antidumping duties may be assessed on the subject imports as a result of these proceedings if the Commission makes an affirmative determination of injury, threat, or material retardation, and if the U.S. Department of Commerce ("Commerce") makes an affirmative determination of subsidization and/or dumping. Questionnaires are available at https://usitc.gov/reports/active import injury questionnaires. Other information pertinent to this proceeding are available at https://ids.usitc.gov/case/8133/investigation/8423.

<u>HPC pea protein</u> covered by this proceeding is high protein content pea protein, which is a protein derived from peas (including, but not limited to, yellow field peas and green field peas) and which contains more than 65 percent protein on a dry weight basis. HPC pea protein may also be identified as, for example, pea protein concentrate, pea protein isolate, hydrolyzed pea protein, pea peptides, and fermented pea protein. Pea protein, including HPC pea protein, has the Chemical Abstracts Service ("CAS") registry number 222400-29-5.

The scope covers HPC pea protein in all physical forms, including all liquid (e.g., solution) and solid (e.g., powder) forms, regardless of packaging.

The scope includes HPC pea protein described above that is blended, combined, or mixed with non-subject pea protein or with other products, including, but not limited to, protein powders, dry beverage blends, and protein fortified beverages. For any such blended, combined, or mixed products, only the HPC pea protein component is covered by the scope of these investigations. HPC pea protein that has been blended, combined, or mixed with other products is included within the scope, regardless of whether the blending, combining, or mixing occurs in third countries.

HPC pea protein that is otherwise within the scope is covered when commingled (i.e., blended, combined, or mixed) with HPC pea protein from sources not subject to this investigation. Only the subject component of the commingled product is covered by the scope.

A blend, combination, or mixture is excluded from the scope if the total HPC pea protein content of the blend, combination, or mixture (regardless of the source or sources) comprises less than 5 percent of the blend, combination, or mixture on a dry weight basis.

HPC pea protein is currently imported under statistical reporting numbers 3504.00.1000, 3504.00.5000, and 2106.10.0000 of the Harmonized Tariff Schedule of the United States (HTSUS). It may also be imported under HTSUS statistical reporting number 2308.00.9890. The HTSUS provisions are for convenience and customs purposes; the written description of the scope is dispositive.

<u>Low protein content pea protein ("LPC pea protein")</u> is pea protein that would otherwise match the definition of HPC pea protein except has a protein content of less than or equal to 65 percent on a dry weight basis.

Reporting of information.--If information is not readily available from your records, provide carefully prepared estimates. If your firm is completing more than one questionnaire (i.e., a producer, importer, purchaser and/or foreign producer questionnaire), you need not respond to duplicated questions.

<u>Confidentiality</u>.--The commercial and financial data furnished in response to this questionnaire that reveal the individual operations of your firm will be treated as confidential by the Commission to the

extent that such data are not otherwise available to the public and will not be disclosed except as may be required by law (see 19 U.S.C. §1677f). Such confidential information will not be published in a manner that will reveal the individual operations of your firm; however, general characterizations of numerical business proprietary information (such as discussion of trends) will be treated as confidential business information only at the request of the submitter for good cause shown.

<u>Verification</u>.--The information submitted in this questionnaire is subject to audit and verification by the Commission. To facilitate possible verification of data, please keep all files, worksheets, and supporting documents used in the preparation of the questionnaire response. Please also retain a copy of the final document that you submit.

Release of information.--The information provided by your firm in response to this questionnaire, as well as any other business proprietary information submitted by your firm to the Commission in connection with this proceeding, may become subject to, and released under, the administrative protective order provisions of the Tariff Act of 1930 (19 U.S.C. § 1677f) and section 207.7 of the Commission's Rules of Practice and Procedure (19 CFR § 207.7). This means that certain lawyers and other authorized individuals may temporarily be given access to the information for use in connection with this proceeding or other import-injury proceedings conducted by the Commission on the same or similar merchandise; those individuals would be subject to severe penalties if the information were divulged to unauthorized individuals.

<u>Valid number error messages.</u>—If you are completing this form in a country that uses periods (".") to delineate multiples of 1000 (e.g., one million would appear as \$1.000.000 rather than \$1,000,000), you may be unable to enter in numbers greater than 999 in numeric form fields. The solution to this data entry issue is to temporarily change your operating system's number formatting to be consistent with the U.S. number formatting system while you complete this form. Detailed instructions on how to resolve this issue is provided at the end of this questionnaire and is available upon request from Tyler Berard (202-205-3354, Tyler.Berard@usitc.gov).

I-1.	Reporting requirementsPlease report below the actual number of hours required and the cost
	to your firm of completing this questionnaire for use by the Office of Management and Budget.

Hours	Dollars

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response, including the time for reviewing instructions, gathering data, and completing and reviewing the questionnaire.

We welcome comments regarding the accuracy of this burden estimate, suggestions for reducing the burden, and any suggestions for improving this questionnaire. Please provide such comments to the Office of Investigations, import_injury@usitc.gov.

I-2. <u>Establishments covered</u>.--Provide the name and address of establishment(s) covered by this questionnaire.

" <u>Establishment"</u> "Each facility of a firm in China involved in the production or export of HPC pea
protein, including auxiliary facilities operated in conjunction with (whether or not physically
separate from) such facilities. Firms operating more than one establishment in China should
combine the data for all establishments into a single report.

i		
i		

Lead attorney(s):

"Related firm" –A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm
that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely
or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed,
or otherwise controlled your firm.

No	Yes	If yes, please name the firm(s) and country(ies) below and, if U.S. producer(s), ensure that they complete the Commission's producer questionnaire.
	-	tersDoes your firm or any related firm import or have any plans to import or the United States?
No	Yes	If yes, please name the firm(s) below and ensure that they complete the Commission's importer questionnaire.
	Ш	
-4 are pub	olicly trade	nation If your firm or any of the entities reported in questions I-2 througed in the United States, please specify the stock exchange and trading merican Depository Receipts, if applicable):

I-7. <u>U.S. importers</u>.--Please provide the names, contacts, telephone numbers, and e-mail addresses of the <u>TEN</u> largest U.S. importers of your firm's HPC pea protein since January 1, 2020.

	Importer's name	Contact person	Email	Telephone	Share of your firm's 2022 U.S. exports (%)
1					
2					
3					
4					
5					
6					
7					
8					
9					
10					

PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from Tyler Berard (202-205-3354, Tyler.Berard@usitc.gov). **Supply all data requested on a calendar-year basis.**

II-1.		nationPlease identify the responsible aff may contact that individual regardin	individual and the manner by which ng the confidential information submitted
	Name		
	Title		
	Email		
	Telephone		

II-2a. <u>Changes in operations.</u>—Please indicate whether your firm has experienced any of the following changes in relation to the production of HPC pea protein since January 1, 2020.

Check	as many as appropriate.	If checked, please describe the nature, timing / duration, and impact on operations of any such reported changes as well as the business reasons for them; leave completely blank if not applicable
	Plant openings	
	Plant closings	
	Prolonged shutdowns	
	Production curtailments	
	Relocations	
	Expansions	
	Acquisitions	
	Consolidations	
	Weather-related or force majeure events	
	Other (e.g., revised labor agreements, technology)	

II-2b.	COVID-19 pandemic. —Has the COVID-19 pandemic or have any government actions taken to
	contain the spread of the COVID-19 virus resulted in changes in your firm's supply chain
	arrangements, production, and shipments (including exports to the United States) relating to
	HPC pea protein? In your response, please discuss the duration and timing of any such changes
	as they relate to your firm's operations.

No	If yes, describe these changes including the impact over time on the (a) supply chain and (b) production and shipments with respect to HPC pea protein.

II-2c. Anticipated changes in operations.--Does your firm anticipate any changes in the character of its operations or organization (as noted above) relating to the production of HPC pea protein in the future?

No	Yes	If yes, supply details as to the likely timing, nature, and significance of such anticipated changes and discuss the underlying assumptions and business reasons for those expectations.

II-3a. <u>Production using same machinery.</u>--Please report your firm's production of products using the same equipment, machinery, or employees as used to produce HPC pea protein, and the combined capacity (both installed and practical capacity) on this shared equipment, machinery, or employees in the periods indicated.

"Installed overall capacity" – The level of production that your establishment(s) could have attained, assuming your firm's optimal product mix, and based solely on existing capital investments, i.e., machinery and equipment that is in place and ready to operate. This capacity measure does <u>not</u> take into account other constraints to production such as existing workforce constraints, availability of raw materials, or downtime for maintenance, repair, and clean-up. This capacity measure is sometimes referred to as "nameplate" or "theoretical" capacity.

"Practical overall capacity" – The level of production that your establishment(s) could reasonably have expected to attain, taking into account your firm's actual product mix over the period. This capacity measure is based on not only existing capital investments, i.e., machinery and equipment that is in place and ready to operate; but also non-capital investment constraints, such as (1) normal operating conditions, including normal downtime for maintenance, repair, and cleanup; (2) your firm's existing in place and readily available labor force; (3) availability of material inputs; and (4) any other constraints that may have limited your firm's ability to produce the reported products. Importantly, this capacity measure is the maximum "practical" production your firm could have achieved without hiring new personnel or expanding the number of shifts operated in the period.

"Practical HPC pea protein capacity" – The level of production of HPC pea protein that your establishment(s) could reasonably have expected to attain. The same assumptions apply to this capacity measure as for practical overall capacity, but only includes the portion of practical overall capacity allocated to the production of HPC pea protein based on the actual product mix experienced over the period.

"Production" – All production in your establishment(s) in China, including production consumed internally within your firm and production for another firm under a toll agreement.

Takes into account	Installed overall capacity	Practical overall capacity	Practical HPC pea protein capacity
Existing capital investments	Yes	Yes	Yes
Product mix	Yes	Yes	Yes
Normal downtime, maintenance, repair and clean-up	No	Yes	Yes
Existing labor force	No	Yes	Yes
Availability of material inputs	No	Yes	Yes
Actual number of shifts and hours operated	No	Yes	Yes
Limited to HPC pea protein	No	No	Yes

II-3a. **Production using same machinery.**—**Continued**

Quantity (in 1,000 pounds dry weight)								
	C	alendar year	January-March					
Item	2020	2021	2022	2022	2023			
Capacity measures: Installed overall capacity ¹								
Practical overall capacity ¹²								
Practical HPC pea protein capacity ^{3 4}	0	0	0	0	0			
Production of: HPC pea protein ^{3 4}	0	0	0	0	0			
Other out-of-scope products: LPC pea protein								
Other legume proteins ⁵								
Other products ⁶								
Subtotal, all out-of-scope products	0	0	0	0	С			
Total production using same machinery or								
workers	0	0	0	0	C			

¹ Data reported for both "installed overall" and "practical overall" capacity should each individually be greater than data reported for total production (last line). Additionally, data reported for "installed overall" capacity should be greater than "practical overall" capacity in every period.

⁵ This line should include any non-p	ea proteins that were blended in with HPC pea protein products. Also, please
identify these other legume proteins:	<u> </u>
⁶ Please identify these products:	

II-3b. **Operating parameters.--**The *practical* overall capacity reported in II-3a is based on the following operating parameters:

Hours per week	Weeks per year

² Please provide details in your response to the question on capacity constraints in question II-3d below that explain the differences reported between "installed" and "practical" overall production capacities.

³ Data entered in question II-9 for this indicator will populate here.

⁴ Data reported for practical HPC pea protein capacity should be greater than the data reported for production of HPC pea protein in each period, if not revise prior to submission to the Commission. Additionally, if your firm reports the production of no other products on the same machinery and using the same workers as HPC pea protein then "practical overall" and "practical HPC pea protein" capacity measures should be equal to each other.

firm's were l report but wa	practical overall capacity over the pending over different periods report ted practical overall capacity. If a cort	ase describe the constraint(s) that set the limit(s) on your eriod reported in question II-3a. If different constraints ed, please specify when each constraint was limiting your estraint was not actually binding over the period reported estalled capacity level, indicate at what level it would have
	traint ck as many as appropriate)	Description (If checked, please describe the details, timing, and dure of the constraint; leave completely blank if not applicable
	Production bottlenecks	
	Existing labor force	
	Supply of material inputs	
	Fuel or energy	
	Storage capacity	
	Logistics/transportation	
	Other constraints (list the specific constraints in the description field)	
and th procu	ne additional actions that would be n	e describe and quantify the amount of time it would take eeded (e.g., hiring new workers, expanding shifts, upply, etc.) for your firm to be able to fully utilize the d in II-3a.

Product s	shifting.—	
	•	a able to switch production (capacity) between HPC pea protein and other sing the same equipment and/or labor?
No	Yes	If yes—(i.e., have produced other products or are able to produce othe products) Please identify other actual or potential products.

II-5.	Capacity checklistPlease check that the capacity numbers reported in question II-3a follow the
	Commission's relevant definitions for capacity.

Item	√ if Yes
Are all three capacity measures reported based on <u>currently installed machinery</u> and equipment (i.e., the reported capacity level would not require additional	
capital investments in order to achieve)?	
Are practical overall capacity and practical HPC pea protein capacity measures reported based on <u>existing labor force</u> (i.e., the reported capacity level would not	
require hiring additional production related workers or adding shifts)?	
Are practical overall capacity and practical HPC pea protein capacity measures based on the actual availability of material inputs?	
Do both practical overall capacity and practical HPC pea protein capacity measures account for normal downtime, maintenance, repair and clean-up	
activities?	
Does the difference between practical overall capacity and practical HPC pea	
protein capacity equal the portion of practical overall capacity that is dedicated	
to the production of out-of-scope products?	

Note: If your firm is not able to answer "yes" to any of the above criteria as it relates to your firm's reported capacity levels, please revise your capacity numbers to be in conformance with the appropriate definition prior to submission to the Commission.

- II-6. <u>Share of sales</u>.--What percentage of your firm's total sales in its most recent fiscal year was represented by sales of HPC pea protein? _____ percent.
- II-7a. **Firm's estimated share of production in China.--**Please estimate the percentage of total production of HPC pea protein in China accounted for by your firm's production in 2022. _____ percent.
- II-7b. <u>Firm's estimated share of exports from China</u>.--Please estimate the percentage of total exports to the United States of HPC pea protein from China accounted for by your firm's exports in 2022. _____ percent.
- II-8. <u>Third country trade actions</u>.--Is the HPC pea protein exported by your firm subject to antidumping/countervailing duty/safeguard findings, remedies, or proceedings?

No	Yes	If yesList the products(s), countries affected, and the date of such findings/remedies/proceedings.

II-9. <u>Trade data</u>.--Report your firm's capacity, production, shipments, and inventories related to the production of HPC pea protein in your establishment(s) in China during the specified periods. Do not include resales of HPC pea protein that your firm did not produce in this question; those data to the degree they are exported to the United States should only be reported in question II-10.

<u>Do not submit data by manufacturing facility if they are in the same country.</u> If your firm has multiple manufacturing establishments within one country, you are required to combine data for those establishments within one foreign producer questionnaire response.

"Shipments"--Shipments of products produced in your establishment(s) in China. Quantities reported should be net of returns.

"Home market commercial shipments"--Shipments, other than internal consumption and transfers to related firms, within China.

"Home market internal consumption/transfers to related firms"--Shipments made to related firms in China, including product consumed internally by your firm.

"Export shipments"--Shipments to destinations outside of the country indicated on page 1 (China), including shipments to related firms.

"Inventories" -- Finished goods inventory, not raw materials or work-in-progress.

Note: Quantity reported in this table should relate to only the pea protein content for any blended products that contain pea protein.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the trade data, as Commission staff may contact your firm regarding questions on the trade data. The Commission may also request that your company submit copies of the supporting documents/records (such as production and sales schedules, inventory records, etc.) used to compile these data.

II-9. <u>Trade data</u>.--Continued.

Quantity (in 1,000 pounds dry weight)									
	Calendar year			Januar	y-March	Projections ¹			
Item	2020	2021	2022	2022	2023	2023	2024		
Practical HPC pea protein capacity ² (A)									
Beginning-of-period inventories (B)									
Production ² (C)									
Home market shipments: Internal consumption/ transfers (D)									
Commercial shipments (E)									
Export shipments: to the United States (F)									
to all other markets (G) ³									
Total exports (H)	0	0	0	0	0	0	(
Total shipments (I)	0	0	0	0	0	0			
End-of-period inventories (J)									

¹ Explain the basis of your firm's projections: _____.

² Report your firm's practical pea protein capacity consistent with the definitions and instruction provided in question II-3a. Data entered for this indicator will populate in question II-3a once reported here.

³ Identify your firm's principal other export markets: _____

II-9. <u>Trade data</u>.--Continued.

RECONCILIATION OF SHIPMENTS, PRODUCTION, AND INVENTORY.--Generally, the data reported for the end-of-period inventories (i.e., line R) should be equal to the beginning-of-period inventories (i.e., line B), plus production (i.e., line C), less total shipments (i.e., lines D, F, H, J, L, and N). Please ensure that any differences are not due to data entry errors in completing this form, but rather actually reflect your firm's records; and also provide any likely explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

	Actual experience						Projections	
	C	alendar yea	r	Januar	y-March	Calendar year		
ltem	2020	2021	2022	2022	2023	2023	2024	
B + C - D - E - F - G - J = should equal								
zero ("0") or provide an explanation.1	0	0	0	0	0	0	0	
¹ Explanation if the calculated fields	above are i	eturning va	lues other t	han zero (i	.e., "0") but a	re noneth	eless	

II-10. <u>Exports to the United States not produced by your firm</u>.--Report your firm's exports to the United States of HPC pea protein that was produced in China but not by your firm during the specified periods. Note these data should <u>not</u> be included in question II-8.

Note: Quantity reported in this table should relate to only the pea protein content for any blended products that contain pea protein.

Quantity (in 1,000 pounds dry weight)							
	Actual experience					Projections	
	Calendar year		January-March		Calendar year		
Item	2020	2021	2022	2022	2023	2023	2024
Exports of HPC pea protein to the United States not produced by your firm ¹ (K)							
¹ List the producer(s)							

II-11. Exports to the United States by product type.--Report your firm's exports to the United States of HPC pea protein by product type in the specified periods.

Quantity (in 1,000 pounds dry weight)						
	Calendar year			January-March		
ltem	2020	2021	2022	2022	2023	
Exports to the United States: Pure HPC pea protein products: Quantity (L)						
Blended HPC pea protein products: Quantity, relating to HPC pea protein (M)						
Quantity, relating to other inputs blended in with the HPC pea protein (N)						

RECONCILIATION OF EXPORTS TO THE UNITED STATES BY PRODUCT TYPE.--Please ensure that the quantities reported for exports to the United States by product type (i.e., lines L and M) in each time period equal the quantities reported for exports to the United States (i.e., lines F through K) in each time period in the previous questions. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

		Calendar year	January-March		
Reconciliation	2020	2021	2022	2022	2023
Quantity: $L + M - F - K = zero ("0"),$					
if not revise.	0	0	0	0	0

II-12.	Other explanationsIf your firm would like to further explain a response to a question in Part II
	for which a narrative box was not provided, please note the question number and the
	explanation in the space provided below. Please also use this space to highlight any issues your
	firm had in providing the data in this section, including but not limited to technical issues with
	the MS Word questionnaire.


Correcting Valid number error messages.—If you are completing this questionnaire in a country that uses periods (".") to delineate multiples of 1000 (e.g., one million would appear as \$1.000.000 instead of as \$1,000,000), you may be unable to enter in numbers greater than 999 in numeric form fields. This issues stem from your computer number formatting setting (e.g., not the MS Word document itself, but the computer from which you are opening up the document). In the United States commas (,) delineate multiples of 1000 and periods (.) delineate fractions less than one. Many EU countries use the reverse where multiples of 1000 are delineated with periods (.) and fractions less than one are delineated with commas (,). This questionnaire is prepared in the United States with the U.S. number formatting. When this formatting interacts with a computer set to EU number formatting, we believe this may cause this issue.

The solution to this data entry issue is to temporarily change your operating system's number formatting to be consistent with the U.S. number formatting system while you complete the questionnaire.

To temporarily change your computer's number settings to U.S. settings, please do the following (for Microsoft Windows Operating system):

- START
- Control Panel
- Region and Language (under Clock, Language, and Region category)
- Format tah
- Change the Format from your existing one (e.g., "Italian (Italy)") to "English (United States)" (see screen shots below)

When you do this the number "twelve million dollars and thirty five cents" would change from \$12.000.000,35 (Italy format) to \$12,000,000.35 (U.S. format), and then there will be no conflict with the USITC foreign producer questionnaire form. When you finish reporting the data then you can close the questionnaire and switch back to your country settings.





HOW TO FILE YOUR QUESTIONNAIRE RESPONSE

This questionnaire is available as a "fillable" form in MS Word format on the Commission's website at:

https://usitc.gov/reports/active import injury questionnaires.

Please do not attempt to modify the format or permissions of the questionnaire document. Please submit the completed questionnaire using one of the methods noted below. If your firm is unable to complete the MS Word questionnaire or cannot use one of the electronic methods of submission, please contact the Commission for further instructions.

• <u>Upload via Secure Drop Box</u>.—Upload the MS Word questionnaire along with a scanned copy of the signed certification page (page 1) through the Commission's secure upload facility:

Web address: https://dropbox.usitc.gov/oinv/ Pin: PEA

• E-mail.—E-mail your questionnaire to Tyler.Berard@usitc.gov; include a scanned copy of the signed certification page (page 1). Submitters are strongly encouraged to encrypt nonpublic documents that are electronically transmitted to the Commission to protect your sensitive information from unauthorized disclosure. The USITC secure drop-box system and the Electronic Document Information System (EDIS) use Federal Information Processing Standards (FIPS) 140-2 cryptographic algorithms to encrypt data in transit. Submitting your nonpublic documents by a means that does not use these encryption algorithms (such as by email) may subject your firm's nonpublic information to unauthorized disclosure during transmission. If you choose a non-encrypted method of electronic transmission, the Commission warns you that the risk of such possible unauthorized disclosure is assumed by you and not by the Commission.

If your firm did not produce or export this product, please fill out page 1, print, sign, and submit a scanned copy to the Commission.

Parties to this proceeding.—If your firm is a party to this proceeding, you are required to serve a copy of the completed questionnaire on parties to the proceeding that are subject to administrative protective order (see 19 CFR § 207.7). A list of such parties may be obtained from the Commission's Secretary (202-205-1802). A certificate of service must accompany the completed questionnaire you submit (see 19 CFR § 207.7).